@article{Lee_Duggan_Neri_Tay_Zepeda_2019, title={Bortezomib maintenance for the treatment of Monoclonal Gammopathy of Renal Significance}, volume={11}, url={https://www.mjhid.org/mjhid/article/view/2019.007}, DOI={10.4084/mjhid.2019.007}, abstractNote={<p>Monoclonal gammopathy of renal significance (MGRS) defines renal disease resulting from monoclonal proteins that are secreted from clonal B cells, that does not meet criteria for lymphoma or multiple myeloma. Recognizing MGRS in clinical practice is important because renal outcomes are poor and treatments targeting the underlying clonal disease have been associated with improved renal survival. In this case report, we present a case of a patient with membranoproliferative glomerulonephritis (MPGN) with IgG-kappa deposition who underwent clone directed treatment in a phased approach with induction and maintenance to achieve renal response. This is one of the first cases to report on MGRS treatment that required extended maintenance therapy.</p>}, number={1}, journal={Mediterranean Journal of Hematology and Infectious Diseases}, author={Lee, Holly and Duggan, Peter and Neri, Ernesta Paola and Tay, Jason and Zepeda, Victor Jimenez}, year={2019}, month={Jan.}, pages={e2019007} }